A Phase I Study to Evaluate Safety, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of XTR004 in Healthy Chinese Volunteers
Latest Information Update: 08 Feb 2022
At a glance
- Drugs XTR 004 (Primary)
- Indications Coronary artery disease; Myocardial ischaemia
- Focus Adverse reactions
- Sponsors Sinotau Pharmaceuticals
Most Recent Events
- 28 Jan 2022 New trial record